Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • MD Brand Connect
  • Micro Labs Launches...

Micro Labs Launches Sitanorm-E, Sitagliptin-Empagliflozin FDC for Uncontrolled Type 2 Diabetes in India

Deeksha BhandariWritten by Deeksha Bhandari Published On 2025-06-06T12:11:57+05:30  |  Updated On 6 Jun 2025 2:45 PM IST
Micro Labs Launches Sitanorm-E, Sitagliptin-Empagliflozin FDC for Uncontrolled Type 2 Diabetes in India
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Micro Labs has announced the launch of Sitanorm-E, a fixed-dose combination (FDC) of Sitagliptin and Empagliflozin. The combination is formulated to address the growing challenge of uncontrolled type 2 diabetes mellitus (T2DM), particularly in patients not achieving adequate glycemic control with metformin alone.

Sitanorm-E tablets, a fixed-dose combination of Sitagliptin and Empagliflozin, has received DCGI approval for the treatment of type 2 diabetes mellitus in patients who are inadequately controlled with metformin alone.

It is available in two strengths—Sitanorm E 10 (Sitagliptin 100 mg + Empagliflozin 10 mg) and Sitanorm E 25 (Sitagliptin 100 mg + Empagliflozin 25 mg)—priced at ₹180 and ₹198 for a strip of 10 tablets.

The launch comes at a time when global treatment guidelines are evolving to prioritize outcomes beyond glycemic control. The American Diabetes Association (ADA)1 and the European Association for the Study of Diabetes (EASD) recommend the use of SGLT2 inhibitors and DPP4 inhibitors, either as monotherapy or in combination, for T2DM patients, especially those with established cardiovascular disease (CVD), chronic kidney disease (CKD), or at high risk of such complications.

Empagliflozin and Sitagliptin: EMpowered to Protect Beyond Glycemic control

The two molecules in Sitanorm-E have well-established clinical benefits:

Empagliflozin a potent, highly selective, sodium glucose cotransporter-2 (SGLT2) inhibitor, is an effective and generally well-tolerated anti-hyperglycaemic agent approved for the treatment of adults with type 2 diabetes (T2D). It has also shown cardio-renal protective effects in multiple large-scale landmark trials such as EMPA-REG OUTCOME, EMPEROR-Reduced/Preserved, and EMPA-KIDNEY. These studies demonstrated reduced risk of cardiovascular death, hospitalization for heart failure, and progression of kidney disease2. Beyond lowering glucose, empagliflozin exerts a favourable effect on a number of beyond-glycaemic outcomes, including reductions in bodyweight and blood pressure.

Sitagliptin, a DPP4 inhibitor, approved in more than 130 countries across the globe and is widely prescribed India and has shown good glycemic efficacy, low hypoglycemia with a neutral effect on cardiovascular risk, as reported in the TECOS trial3.

Addressing India’s Diabetes Burden

India is facing a massive diabetes crisis. With an estimated 74.9 million adults (aged 20–79 years) currently living with diabetes, the country ranks second globally, after China. According to the International Diabetes Federation (IDF)4, one in every seven diabetic adults worldwide is Indian. The condition impacts nearly one in three households, straining both personal finances and the national healthcare system5.

Indian studies revealed that over 50% of diabetes patients have poor glycemic control (HbA1c >8%) and coexisting issues like hypertension and dyslipidemia. Despite treatment, 72.7% still had HbA1c above 7%. Infrequent monitoring further worsens outcomes, increasing the risk of serious vascular complications and higher mortality6.

Uncontrolled diabetes can lead to serious complications such as heart disease, kidney failure, blindness, and amputations. Hence, timely and effective management is crucial.

Speaking to Medical Dialogues, Mr. Satish G. Mansukhani, Sr. Vice President – Sales & Marketing at Micro Labs, said “Sitanorm -E provides an excellent opportunity for patients with T2DM with co-morbid conditions like CKD & CVD. This therapy also offers end-organ protection in uncontrolled type 2 diabetes mellitus.”

Micro Labs is one of India's leading pharmaceutical companies with a strong presence in cardiology, diabetology, neurology, and ophthalmology. The company, headquartered in Bengaluru, Karnataka, is known for its flagship brand Dolo 650, and continues to invest in research-backed, patient-centric therapies across various specialties.

References:

1) Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, Hattersley AT, Jones AG, Shields BM; MASTERMIND consortium. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. Lancet Digit Health. 2022 Dec;4(12):e873-e883. doi: 10.1016/S2589-7500(22)00174-1. PMID: 36427949.

2) Colbert GB, Madariaga HM, Gaddy A, Elrggal ME, Lerma EV. Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy. Ther Clin Risk Manag. 2023 Feb 2;19:133-142. doi: 10.2147/TCRM.S398163. PMID: 36756278; PMCID: PMC9901477.

3) Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586. doi: 10.1056/NEJMx150029. PMID: 26052984.

4) International Diabetes Federation. IDF Diabetes Atlas, 11th edn. Brussels, Belgium: 2025. Available at: https://diabetesatlas.org

5) Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021 Nov;69(11):2932-2938. doi: 10.4103/ijo.IJO_1627_21. PMID: 34708726; PMCID: PMC8725109.

6) Muralidharan, Shrikanth. Diabetes and current Indian scenario: A narrative review. Journal of Diabetology 15(1):p 12-17, January-March 2024. | DOI: 10.4103/jod.jod_93_23

sitanorm Esitagliptinempagliflozindiabetest2dSitanorm E 10Sitanorm E 25ADAEASDsglt2idpp4icvdckdhba1cglycemic controldiabetes medicinediabetes managementSatish G. Mansukhanimicro labs
Deeksha Bhandari
Deeksha Bhandari

    Deeksha Bhandari is a Writer at Medical Dialogues and completed B.Sc (Hons) in Microbiology from Delhi University and PG in Food Sciences

    Show Full Article
    Next Story

    Editorial

    How to Improve Adherence in Hypertensive Patients? Bridging the Gap with CONNECT Tool

    How to Improve Adherence in Hypertensive Patients? Bridging the Gap with CONNECT Tool

    Vestibular Migraine: Clinical Update and Role of Buccal Prochlorperazine

    Vestibular Migraine: Clinical Update and Role of Buccal Prochlorperazine

    U.S. FDA Drug Safety Alert: Warning Issued for Severe Itching After Stopping Long-Term Cetirizine or Levocetirizine Use

    U.S. FDA Drug Safety Alert: Warning Issued for Severe Itching After Stopping Long-Term Cetirizine or...

    Aspirin in Primary Prevention: Prudent Guideline-Based Approach

    Aspirin in Primary Prevention: Prudent Guideline-Based Approach

    Prediabetes and CKD: An Overlooked Interaction in Early Metabolic Disease

    Prediabetes and CKD: An Overlooked Interaction in Early Metabolic Disease

    View All

    Journal Club Today

    Weight-Loss Surgery Doubles Self-Esteem Scores: Study Finds

    Weight-Loss Surgery Doubles Self-Esteem Scores: Study Finds

    View All

    Health News Today

    Health Bulletin 24/June/2025

    Health Bulletin 24/June/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok